Fenofibrate Represses Interleukin-17 and Interferon-γ Expression and Improves Colitis in Interleukin-10-Deficient Mice

Gastroenterology

Volumn 133, Issue 1, 2007, Pages 108-123

  Lee, Jimmy W ^a   Bajwa, Poonam J ^a   Carson, Monica J ^a   Jeske, Daniel R ^b   Cong, Yingzi ^c   Elson, Charles O ^c   Lytle, Christian ^a   Straus, Daniel S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CCL20 CHEMOKINE; CHEMOKINE; FENOFIBRATE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GW 0742; INTERLEUKIN 10; INTERLEUKIN 17; LIGAND; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CELL COUNT; COLITIS; COLON; COLORECTAL CANCER; CONTROLLED STUDY; CRYPT CELL; DISEASE COURSE; DRUG EFFECT; EPITHELIUM CELL; GENE EXPRESSION; GENE REPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; LYMPHOCYTE; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN CELL; T LYMPHOCYTE;

EID: 34447101284     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2007.03.113     Document Type: Article

References (73)

1. Kota B.P., Huang T.H., and Roufogalis B.D. An overview on biological mechanisms of PPARs. Pharmacological Res 51 (2005) 85-94
2. Willson T.M., Brown P.J., Sternbach D.D., and Henke B.R. The PPARs: from orphan receptors to drug discovery. J Med Chem 43 (2000) 527-550
3. Xu H.E., Lambert M.H., Montana V.G., Parks D.J., Blanchard S.G., Brown P.J., Sternbach D.D., Lehmann J.M., Wisely G.B., Willson T.M., Kliewer S.A., and Milburn M.V. Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. Available: http://www.molecule.org/. Mol Cell 3 (1999) 397-403
4. Chawla A., Lee C.H., Barak Y., He W., Rosenfeld J., Liao D., Han J., Kang H., and Evans R.M. PPARδ is a very low-density lipoprotein sensor in macrophages. Proc Natl Acad Sci U S A 100 (2003) 1268-1273
5. Gupta R.A., Tan J., Krause W.F., Geraci M.W., Willson T.M., Dey S.K., and DuBois R.N. Prostacyclin-mediated activation of peroxisome proliferators-activated receptor δ in colorectal cancer. Proc Natl Acad Sci U S A 97 (2000) 13275-13280
6. Oliver Jr. W.R., Shenk J.L., Snaith M.R., Russell C.S., Plunket K.D., Bodkin N.L., Lewis M.C., Winegar D.A., Sznaidman M.L., Lambert M.H., Xu H.E., Sternbach D.D., Kliewer S.A., Hansen B.C., and Willson T.M. A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport. Proc Natl Acad Sci U S A 98 (2001) 5306-5311
7. Sznaidman M.L., Haffner C.D., Maloney P.R., Fivush A., Chao E., Goreham D., Sierra M.L., LeGrumelec C., Xu H.E., Montana V.G., Lambert M.H., Willson T.M., Oliver Jr. W.R., and Sternbach D.D. Novel selective small molecular agonists for peroxisome proliferator-activated receptor δ (PPARδ)-synthesis and biological activity. Bioorg Med Chem Lett 13 (2003) 1517-1521
8. Wang Y.X., Lee C.H., Tiep S., Yu R.T., Ham J., Kang H., and Evans R.M. Peroxisome-proliferator-activated receptor δ activates fat metabolism to prevent obesity. Cell 113 (2003) 159-170
9. Tanaka T., Yamamoto J., Iwasaki S., Asaba H., Hamura H., Ikeda Y., Watanabe M., Magoori K., Ioka R.X., Tachibana K., Watanabe Y., Uchiyama Y., Sumi K., Iguchi H., Ito S., Doi T., Hamakubo T., Naito M., Auwerx J., Yanagisawa M., Kodama T., and Sakai J. Activation of peroxisome proliferator-activated receptor δ induces fatty acid β-oxidation in skeletal muscle and attenuates metabolic syndrome. Proc Natl Acad Sci U S A 100 (2003) 15924-15929
10. Daynes R.A., and Jones D.C. Emerging roles of PPARs in inflammation and immunity. Nature Rev Immunol 2 (2002) 748-759
11. Su C.G., Wen X., Bailey S.T., Jiang W., Rangwala S.M., Keilbaugh S.A., Flanigan A., Murthy S., Lazar M.A., and Wu G.D. A novel therapy for colitis utilizing PPAR-γ ligands to inhibit the epithelial inflammatory response. J Clin Invest 104 (1999) 383-389
12. Lytle C., Tod T.J., Vo K.T., Lee J.W., Atkinson R.D., and Straus D.S. The peroxisome proliferators-activated receptor γ ligand rosiglitazone delays the onset of inflammatory bowel disease in mice with interleukin 10 deficiency. Inflamm Bowel Dis 11 (2005) 231-243
13. Li A.C., Binder C.J., Gutierrez A., Brown K.K., Plotkin C.R., Pattison J.W., Valledor A.F., Davis R.A., Willson T.M., Witztum J.L., Palinski W., and Glass C.K. Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARα, β/δ, and γ. J Clin Invest 114 (2004) 1564-1576
14. Lovett-Racke A.E., Hussain R.Z., Northrop S., Choy J., Rocchini A., Matthes L., Chavis J.A., Diab A., Drew P.D., and Racke M.K. Peroxisome proliferator-activated receptor α agonists as therapy for autoimmune disease. J Immunol 172 (2004) 5790-5798
15. Lo Verme J., Fu J., Astarita G., La Rana G., Russo R., Calignano A., and Piomelli D. The nuclear receptor peroxisome proliferator-activated receptor-α mediates the anti-inflammatory actions of palmitolyethanolamide. Mol Pharmacol 67 (2005) 15-19
16. Li S., Gokden N., Okusa M.D., Bhatt R., and Portilla D. Anti-inflammatory effect of fibrate protects from cisplatin-induced ARF. Am J Physiol 289 (2005) F469-F480
17. Cuzzocrea S., Di Paola R., Mazzon E., Genovese T., Muia C., Centorrino T., and Caputi A.P. Role of endogenous and exogenous ligands for the peroxisome proliferators activated receptors α (PPAR-α) in the development of inflammatory bowel disease in mice. Lab Invest 84 (2004) 1643-1654
18. Welch J.S., Ricote M., Akiyama T.E., Gonzalez F.J., and Glass C.K. PPARγ and PPARδ negatively regulate specific subsets of lipopolysaccharide and INF-γ target genes in macrophages. Proc Natl Acad Sci U S A 100 (2003) 6712-6717
19. Polak P.E., Kalinin S., Dello Russo C., Gavrilyuk V., Sharp A., Peters J.M., Richardson J., Willson T.M., Weinberg G., and Feinstein D.L. Protective effects of a peroxisome proliferators-activated receptor-β/δ agonist in experimental autoimmune encephalomyelitis. J Neuroimmunol 168 (2005) 65-75
20. Ricote M., Li A.C., Willson T.M., Kelly C.J., and Glass C.K. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature 391 (1998) 79-82
21. Delerive P., De Bosscher K., Besnard S., Vanden Berghe W., Peters J.M., Gonzalez F.J., Fruchart J.C., Tedgui A., Haegeman G., and Staels B. Peroxisome proliferator-activated receptor α negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-κB and AP-1. J Biol Chem 274 (1999) 32048-32054
22. Pascual G., Fong A.L., Ogawa S., Gamliel A., Li A.C., Perissi V., Rose D.W., Willson T.M., Rosenfeld M.G., and Glass C.K. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-γ. Nature 437 (2005) 759-763
23. Wang Q., Herrera-Ruiz D., Mathis A.S., Cook T.J., Bhardwaj R.K., and Knipp G.T. Expression of PPAR and RXR isoforms and fatty acid transporting proteins in the rat and human gastrointestinal tracts. J Pharmacol Sci 94 (2005) 363-372
24. Escher P., Braissant O., Basu-Modak S., Michalik L., Wahli W., and Desvergne B. Rat PPARs: quantitative analysis in adult rat tissues and regulation in fasting and refeeding. Endocrinology 142 (2001) 4195-4202
25. Gupta R.A., Wang D., Katkuri S., Wang H., Dey S.K., and DuBois R.N. Activation of nuclear hormone receptor peroxisome proliferator-activated receptor-δ accelerates intestinal adenoma growth. Nat Med 10 (2004) 245-247
26. Harman F.S., Nicol C.J., Marin H.E., Ward J.M., Gonzalez F.J., and Peters J.M. Peroxisome proliferator-activated receptor-δ attenuates colon carcinogenesis. Nat Med 10 (2004) 481-483
27. Marin H.E., Peraza M.A., Billin A.N., Willson T.M., Ward J.M., Kennett M.J., Gonzalez F.J., and Peters J.M. Ligand activation of peroxisome proliferator-activated receptor β inhibits colon carcinogenesis. Cancer Res 66 (2006) 4394-4401
28. + TH1-like responses. J Clin Invest 98 (1996) 1010-1020
29. Davidson N.J., Hudak S.A., Lesley R.E., Menon S., Leach M.W., and Rennick D.M. IL-12, but not IFN-γ, plays a major role in sustaining the chronic phase of colitis in IL-10-deficient mice. J Immunol 161 (1998) 3143-3149
30. Spencer D.M., Veldman G.M., Banerjee S., Willis J., and Levine A.D. Distinct inflammatory mechanisms mediate early versus late colitis in mice. Gastroenterology 122 (2002) 94-105
31. Bristol I.J., Farmer M.A., Cong Y., Zheng X.X., Strom T.B., Elson C.O., Sundberg J.P., and Leiter E.H. Heritable susceptibility for colitis in mice induced by IL-10 deficiency. Inflamm Bowel Dis 6 (2000) 290-302
32. + effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 6 (2005) 1123-1132
33. Bettelli E., Carrier Y., Gao W., Korn T., Strom T.B., Oukka M., Weiner H.L., and Kuchroo V.K. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441 (2006) 235-238
34. Mangan P.R., Harrington L.E., O'Quinn D.B., Helms W.S., Bullard D.C., Elson C.O., Hatton R.D., Wahl S.M., Schoeb T.R., and Weaver C.T. Transforming growth factor-β induces development of the TH17 lineage. Nature 441 (2006) 231-234
35. Yen D., Cheung J., Scheerens H., Poulet F., McClanahan T., McKenzie B., Kleinschek M.A., Owyang A., Mattson J., Blumenschein W., Murphy E., Sathe M., Cua D.J., Kastelein R.A., and Rennick D. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest 116 (2006) 1310-1316
36. McKenzie B.S., Kastelein R.A., and Cua D.J. Understanding the IL-23-IL-17 pathway. Trends Immunol 27 (2005) 17-23
37. Duez H., Chao Y.S., Hernandez M., Torpier G., Poulain P., Mundt S., Mallat Z., Teissier E., Burton C.A., Tedgui A., Fruchart J.C., Fievet C., Wright S.D., and Staels B. Reduction of atherosclerosis by the peroxisome proliferator-activated receptor α agonist fenofibrate in mice. J Biol Chem 277 (2002) 48051-48057
38. Lee S.S., Pineau T., Drago J., Lee E.J., Owens J.W., Kroetz D.L., Fernandez-Salguero P.M., Westphal H., and Gonzalez F.J. Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol Cell Biol 15 (1995) 3012-3022
39. English D., and Andersen B.R. Single-step separation of red blood cells, granulocytes and mononuclear leukocytes on discontinuous density gradient of ficoll-hypaque. J Immunol Methods 5 (1974) 249
40. + T cells induce or protect from chronic intestinal inflammation in C.B-17 scid mice. Int Immunol 5 (1993) 1461-1471
41. Li J., Kudsk K.A., Gocinski B., Dent D., Glezer J., and Langkamp-Henken B. Effects of parenteral and enteral nutrition on gut-associated lymphoid tissue. J Trauma 39 (1995) 44-52
42. Sander B., Andersson J., and Andersson U. Assessment of cytokines by immunofluorescence and the paraformaldehyde-saponin procedure. Immunol Rev 119 (1991) 65-93
43. Hsiang C.H., and Straus D.S. Cyclopentenone causes cell cycle arrest and represses cyclin D1 promoter activity in MCF-7 breast cancer cells. Oncogene 21 (2002) 2122-2126
44. Majumder S., Zhou L.Z., Chaturvedi P., Babcock G., Aras S., and Ransohoff R.M. p48/STAT-1 alpha-containing complexes play a predominant role in induction of IFN-γ-inducible protein, 10kDA (IP-10) by IFN-γ alone or in synergy with TNF-α. J Immunol 161 (1998) 4736-4744
45. Kliewer S.A., Forman B.M., Blumberg B., Ong E.S., Borgmeyer U., Mangelsdorf D.J., Umesono K., and Evans R.M. Differential expression and activation of a family of murine peroxisome proliferators-activated receptors. Proc Natl Acad Sci U S A 91 (1994) 7344-7359
46. Fitzmaurice G.M., Laird N.M., and Ware J.H. Applied longitudinal analysis (2004), John Wiley and Sons, Hoboken, NJ 163-178
47. Adachi M., Kurotani R., Morimura K., Shah Y., Sanford M., Madison B.B., Gumicio D.L., Marin H.E., Peters J.M., Young H.A., and Gonzalez F.J. Peroxisome proliferator activated receptor γ in colonic epithelial cells protects against experimental inflammatory bowel disease. Gut 55 (2006) 1104-1113
48. Shiraki M., Aihara H., Kinouchi Y., Takahashi S., Oki M., Noguchi M., Takahashi K., Miyazaki J., and Shimosegawa T. IL-12 p40 prevents the development of chronic enterocolitis in IL-10 deficient mice. Lab Invest 84 (2004) 1491-1500
49. Cunard R., DiCampli D., Archer D.C., Stevenson J.L., Ricote M., Glass C.K., and Kelly C.J. WY14,643, a PPARα ligand, has profound effects on immune response in vivo. J Immunol 169 (2002) 6806-6812
50. Yang Q., Xie Y., Eriksson A.M., Nelson B.D., and DePierre J.W. Further evidence for the involvement of inhibition of cell proliferation and development in thymic and splenic atrophy induced by the peroxisome proliferators perfluoroctanoic acid in mice. Biochem Pharmacol 62 (2001) 1133-1140
51. Jones D.C., Ding X., and Daynes R.A. Nuclear receptor peroxisome proliferators-activated receptor α (PPARα) is expressed in resting murine lymphocytes. The PPARα in T and B lymphocytes is both transactivation and transrepression competent. J Biol Chem 277 (2002) 6838-6845
52. Cunard R., Ricote M., DiCampli D., Archer D.C., Kahn D.A., Glass C.K., and Kelly C.J. Regulation of cytokine expression by ligands of peroxisome proliferators activated receptors. J Immunol 168 (2002) 2795-2802
53. IL-17 cells mediate chronic colitis. Gastroenterology 130 Suppl 2 (2006) A113
54. -/- mice. J Immunol 171 (2003) 1401-1406
55. Singh U.P., Sing S., Iqbal N., Weaver C.T., McGhee J.R., and Lillard Jr. J.W. IFN-γ-inducible chemokines enhance adaptive immunity and colitis. J Interferon Cytokine Res 23 (2003) 591-600
56. Uguccioni M., Gionchetti P., Robbiani D.F., Rizzello F., Peruzzo S., Campieri M., and Baggiolini M. Increased expression of IP-10, IL-8, MCP-1, and MCP-3 in ulcerative colitis. Am J Pathol 155 (1999) 331-336
57. Brown P.J., Stuart W., Hurley K.P., Lewis M.C., Winegar D.A., Wilson J.G., Wilkison W.O., Ittoop O.R., and Willson T.M. Identification of a subtype of selective human PPARα agonist through parallel-array synthesis. Bioorg Med Chem Lett 11 (2001) 1225-1227
58. Fujino S., Andoh A., Bamba S., Ogawa A., Hata K., Araki Y., Bamba T., and Fujiyama Y. Increased expression of interleukin 17 in inflammatory bowel disease. Gut 52 (2003) 65-70
59. Fuss I.J., Becker C., Yang Z., Groden C., Hornung R.L., Heller F., Neurath M.F., Strober W., and Mannon P.J. Both IL-12p70 and IL-23 are synthesized during active Crohn's disease and are down-regulated by treatment with anti-IL-12 p40 monoclonal antibody. Inflamm Bowel Dis 12 (2006) 9-15
60. Uhlig H.H., McKenzie B.S., Hue S., Thompson C., Joyce-Shaikh B., Stepankova R., Robinson N., Buonocore S., Tlaskalova-Hogenova H., Cua D.J., and Powrie F. Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology. Immunity 25 (2006) 309-318
61. Marx N., Kehrle B., Kohlhammer K., Grub M., Koenig W., Homback V., Libby P., and Plutzky J. PPAR activators as anti-inflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis. Circ Res 90 (2002) 703-710
62. Dwinell M.B., Lugering N., Eckmann L., and Kagnoff M.F. Regulated production of interferon-inducible T-cell chemoattractants by human intestinal epithelial cells. Gastroenterology 120 (2001) 49-59
63. Izadpanah A., Dwinell M.B., Eckmann L., Varki N.M., and Kagnoff M.F. Regulated MIP-3α/CCL20 production by human intestinal epithelium: mechanism for modulating mucosal immunity. Am J Physiol Gastro Liver Physiol 280 (2001) G710-G719
64. Kaser A., Ludwiczek O., Holzmann S., Moschen A.R., Weiss G., Enrich B., Graziadei I., Dunzendorfer S., Wiedermann C.J., Murzl E., Grasl E., Jasarevic Z., Romani N., Offner F.A., and Tilg H. Increased expression of CCL20 in human inflammatory bowel disease. J Clin Immunol 24 (2004) 74-85
65. Kwon J.H., Keates S., Bassani L., Mayer L.F., and Keates A.C. Colonic epithelial cells are a major site of macrophage inflammatory protein 3α (MIP-3α) production in normal colon and inflammatory bowel disease. Gut 51 (2002) 818-826
66. Janeway C.A., Travers P., Walpot M., and Shlomchik M.J. Induced innate response to infection. Immunobiology. 6th ed (2005), Garland Science, New York 77-90
67. + T lymphocytes are preferentially recruited to the ileum in Crohn's disease. Gut 53 (2004) 1287-1294
68. Leung T.H., Hoffmann A., and Baltimore D. One nucleotide in a κB site can determine cofactor specificity for NF-κB dimmers. Cell 118 (2004) 453-464
69. Kwon J.H., Keates S., Simeonidis S., Grall F., Libermann T.A., and Keates A.C. ESE-1, an enterocyte-specific Ets transcription factor, regulates MIP-3α gene expression in Caco-2 human colonic epithelial cells. J Biol Chem 278 (2003) 875-884
70. Wu G.D., Lai E.J., Huang N., and Wen X. Oct-1 and CCAAT/enhancer-binding protein (C/EBP) bind to overlapping elements within the interleukin-8 promoter. The role of Oct-1 as a transcriptional repressor. J Biol Chem 272 (1997) 2396-2403
71. Wood L.D., and Richmond A. Constitutive and cytokine-induced expression of the melanoma growth stimulatory activity/GROα gene requires both NF-κB and novel constitutive factors. J Biol Chem 270 (1995) 30619-30626
72. Juge-Aubry C., Pernin A., Favez T., Burger A.G., Wahli W., Meier C.A., and Desvergne B. DNA binding properties of peroxisome proliferator-activated receptor subtypes on various natural peroxisome proliferator response elements. Importance of 5'-flanking regions. J Biol Chem 272 (1997) 25252-25259
73. Dressel U., Allen T.L., Pippal J.B., Rohde P.R., Lau P., and Muscat G.E. The peroxisome proliferator-activated receptor β/δ agonist, GW501516, regulates the expression of genes involved in lipid catabolism and energy uncoupling in skeletal muscle cells. Mol Endocrinol 17 (2003) 2477-2493